Client and biotechnology innovator Progenity completed a initial public offering on NASDAQ (PROG) with a net of more than $37 million. Progenity innovates in women’s health, gastrointestinal health and oral biotherapeutics, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions.

Procopio life sciences attorney and Ph.D. scientist Xiaofan (Frank) Yang led the intellectual property due diligence on the IPO, along with Pattric Rawlins, Steve Beuerle, and Steve Untiedt. Learn more in Progenity’s press release.